Hansdotter Oy

New venture capitalist will bring completely new service model to biotechnology and health technology growth companies

Share

The Nordic countries have a well-established tradition of making capital investments in early-stage growth companies in the ICT sector. In the field of biotechnology and health technology, however, venture capital investments have been significantly more difficult to obtain. Almaral, a new Finnish-based private equity investor, is a one-stop-shop for growth-minded Nordic biotech companies.

It is clear that there is a lack of angel investor capital in the biotech industry. Besides investments, early-stage biotech companies also need guidance in risk management, building up long-term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.

“Almaral is not your average venture capital company. We create value for our clients by answering the strategic and operational questions that a startup company can face in its early stages. Our team has excellent business knowledge and a solid understanding of the biotechnology industry. We have money, but we also know how to use it wisely. We have a unique network of partners and advisors to support our clients in their operational functions and to expand internationally,” says CEO Dr Maria Severina.

The investor team has exceptionally strong evidence of success

Almaral's investment partners have strong evidence of success in the internationally attractive biotech industry. In just a couple of decades, CEO Maria Severina managed to build HyTest into an international success story. Developing antibodies and antigens, the company grew from a two-person startup to one of Finland's most profitable companies. A year ago, HyTest was sold to Chinese Minday for hundreds of millions of euros. Chairman of the Board of Almaral

Alex Michine has been promoting future technologies for the global bioeconomy and has been an active spokesperson for the potential of cross-disciplinary collaboration. He has founded and successfully ran three biotech/cleantech SMEs, including since 2008, MetGen, which won the Frost and Sullivan European Industrial Enzymes Technology Innovation Award.

“We have been highly successful in our business. I believe the main reason for our success has been that we have focused on what we do best and have had the courage to trust good partners in many business support services. In addition to financing, we now want to offer this same model to our own customers,” says Severina.

Contact information:

Email: info@almaral.eu

For interviews: Maria Severina, +358405540127

Keywords

About Hansdotter Oy

Hansdotter Oy
Hansdotter Oy
Linnankatu 3
20100 TURKU

https://hansdotter.fi

Almaral invests in early-stage biotechnology and life sciences startups. Along with investments Almaral offers guidance in risk management, building up long term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.

www.almaral.eu

Subscribe to releases from Hansdotter Oy

Subscribe to all the latest releases from Hansdotter Oy by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Hansdotter Oy

New venture capitalist focusing on health technology makes its first investment in point-of-care analytics8.6.2022 10:37:42 EEST | Press release

Almaral Oy, founded in spring 2022 and focusing on health technology venture capital and business support services, has made a significant investment in the Finnish deep-tech startup Fepod Oy Ltd. The company’s electrochemical analysis method allows healthcare professionals to measure the true concentration of paracetamol, opioids, and other pain medicine in the blood directly at the point of care, and the result is available in seconds. Fepod has its sights set on the 100-billion-euro global diagnostics market. Of this total market, the share of point-of-care analytics is currently around 43% and is growing at an annual rate of over 9%.

Uusi terveysteknologiaan keskittyvä pääomasijoittaja löysi ensimmäisen sijoituskohteen vierianalytiikasta8.6.2022 10:03:47 EEST | Tiedote

Keväällä perustettu terveysteknologian pääomasijoittamiseen ja liiketoiminnan tukipalveluihin keskittyvä Almaral Oy on tehnyt merkittävän sijoituksen suomalaiseen Fepod Oy Ltd:iin. Yhtiön kehittämä sähkökemiallinen vierianalytiikka (point-of-care) tuo terveydenhuollon ammattilaisille mahdollisuuden mitata parasetamolin, opioidien ja muiden kipulääkkeiden todellista pitoisuutta veressä hoitopisteessä. Tulos on saatavilla sekunneissa. Fepod tähtää globaaleille 100 miljardin euron markkinoille. Vierianalytiikan osuus markkinoista on tällä hetkellä noin 43 prosenttia ja yli 9 %:n vuosittaisessa kasvussa.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom